David P. Humphreys

2.1k total citations · 1 hit paper
38 papers, 1.4k citations indexed

About

David P. Humphreys is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Ecology. According to data from OpenAlex, David P. Humphreys has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 22 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Ecology. Recurrent topics in David P. Humphreys's work include Monoclonal and Polyclonal Antibodies Research (22 papers), Protein purification and stability (12 papers) and Bacteriophages and microbial interactions (8 papers). David P. Humphreys is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), Protein purification and stability (12 papers) and Bacteriophages and microbial interactions (8 papers). David P. Humphreys collaborates with scholars based in United Kingdom, Egypt and United States. David P. Humphreys's co-authors include Peter C. Fineran, Tim R. Blower, George P. C. Salmond, I. J. Foulds, Kathryn S. Lilley, Peter A. Lund, Paul E. Stephens, Andrew Mountain, Neil Weir and Dominic J. Glover and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemical Journal.

In The Last Decade

David P. Humphreys

38 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The phage abortive infection system, ToxIN, functions as a protein–RNA toxin–antitoxin pair

2009 412 citations Peter C. Fineran, Tim R. Blower et al. profile →

Peers

Countries citing papers authored by David P. Humphreys

Since Specialization

Citations

This map shows the geographic impact of David P. Humphreys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David P. Humphreys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David P. Humphreys more than expected).

Fields of papers citing papers by David P. Humphreys

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David P. Humphreys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David P. Humphreys. The network helps show where David P. Humphreys may publish in the future.

Co-authorship network of co-authors of David P. Humphreys

This figure shows the co-authorship network connecting the top 25 collaborators of David P. Humphreys. A scholar is included among the top collaborators of David P. Humphreys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David P. Humphreys. David P. Humphreys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life 2023 ·mAbs ·(unknown), (unknown), (unknown), Joanne Compson, (unknown), (unknown), Asher Maroof, (unknown), Karelle Ménochet, (unknown), (unknown), (unknown), (unknown), (unknown), Mark Ellis, (unknown), David P. Humphreys, Sam Heywood	3
2	A comparative analysis of recombinant Fab and full‐length antibody production in Chinese hamster ovary cells 2021 ·Biotechnology and Bioengineering ·(unknown), (unknown), (unknown), (unknown), Mark Ellis, (unknown), David P. Humphreys, Paul E. Stephens, (unknown), James H. White, Alan J. Dickson, C. Mark Smales	9
3	On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation 2021 ·Communications Biology ·(unknown), (unknown), Tania F. Rowley, Robert Oldham, Sonya James, (unknown), Ruth R. French, Alison Turner, Stephen A. Beers, David P. Humphreys, Mark S. Cragg	17
4	Escherichia coli “TatExpress” strains export several g/L human growth hormone to the periplasm by the Tat pathway 2019 ·Biotechnology and Bioengineering ·(unknown), (unknown), (unknown), Douglas F. Browning, (unknown), (unknown), (unknown), (unknown), (unknown), David P. Humphreys, Stephen Busby, Colin Robinson	20
5	Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions 2018 ·Communications Biology ·Tania F. Rowley, (unknown), Mike Aylott, Robert Griffin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Oliver Zaccheo, Gianluca Fossati, Katharine Cain, Andrew M. Ventom, Hanna Hailu, Eleanor J. Ward, (unknown), Frank R. Brennan, (unknown), David P. Humphreys	20
6	High prevalence of subclass-specific binding and neutralizing antibodies against <em>Clostridium difficile</em> toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic <em>C. difficile</em> infection 2017 ·Clinical and Experimental Gastroenterology ·Tanya Monaghan, Ola H. Negm, (unknown), (unknown), Clifford C. Shone, David P. Humphreys, K. Ravi Acharya, Mark H. Wilcox	10
7	A simple method for measuring immune complex-mediated, Fc gamma receptor dependent antigen-specific activation of primary human T cells 2017 ·Journal of Immunological Methods ·Fabian Junker, Sinduya Krishnarajah, Omar Qureshi, David P. Humphreys, (unknown)	6
8	Antibodies for Treatment of Clostridium difficile Infection 2014 ·Clinical and Vaccine Immunology ·David P. Humphreys, Mark H. Wilcox	29
9	Relative stabilities of IgG1 and IgG4 Fab domains: Influence of the light–heavy interchain disulfide bond architecture 2012 ·Protein Science ·(unknown), Ralph Adams, (unknown), (unknown), David P. Humphreys, Andrew G. Popplewell, Alastair D. G. Lawson, Alistair J. Henry	18
10	Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation 2012 ·Protein Engineering Design and Selection ·(unknown), Katharine Cain, Sam Heywood, Joanne Compson, (unknown), Ralph Adams, David P. Humphreys	35
11	Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability 2012 ·Journal of Biological Chemistry ·(unknown), C. Mark Smales, Alistair J. Henry, Paul E. Stephens, Shauna West, David P. Humphreys	25
12	A processed noncoding RNA regulates an altruistic bacterial antiviral system 2011 ·Nature Structural & Molecular Biology ·Tim R. Blower, Xue Pei, Francesca L. Short, Peter C. Fineran, David P. Humphreys, Ben F. Luisi, George P. C. Salmond	106
13	Alternative antibody Fab′ fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering 2007 ·Protein Engineering Design and Selection ·David P. Humphreys, Sam Heywood, Alistair J. Henry, (unknown), Pari Antoniw, Roger Palframan, Kevin Greenslade, Bruce Carrington, (unknown), (unknown), Shauna West, (unknown)	37
14	A plasmid system for optimization of Fab′ production in Escherichia coli: importance of balance of heavy chain and light chain synthesis 2002 ·Protein Expression and Purification ·David P. Humphreys, Bruce Carrington, (unknown), (unknown), (unknown), Bryan John Smith, Lloyd King, (unknown), Alastair D. G. Lawson, Andrew G. Popplewell	39
15	High-Level Periplasmic Expression in Escherichia coli Using a Eukaryotic Signal Peptide: Importance of Codon Usage at the 5′ End of the Coding Sequence 2000 ·Protein Expression and Purification ·David P. Humphreys, (unknown), Andrew P. Chapman, (unknown), Bryan John Smith, Lloyd King, David Glover, (unknown), Paul E. Stephens	55
16	Mutations indsbAanddsbB, but notdsbC, lead to an enhanced sensitivity ofEscherichia colito Hg²⁺and Cd²⁺ 1999 ·FEMS Microbiology Letters ·(unknown), David P. Humphreys, Peter A. Lund	38
17	Efficient site specific removal of a C-terminal FLAG fusion from a Fab′ using copper(II) ion catalysed protein cleavage 1999 ·Protein Engineering Design and Selection ·David P. Humphreys, Bryan John Smith, Lloyd King, Shauna West, (unknown), Paul E. Stephens	21
18	Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab′ expression levels, tail piece sequences and growth conditions 1997 ·Journal of Immunological Methods ·David P. Humphreys, Andrew P. Chapman, (unknown), (unknown), Paul E. Stephens	14
19	Co‐expression of human protein disulphide isomerase (PDI) can increase the yield of an antibody Fab′ fragment expressed inEscherichia coli 1996 ·FEBS Letters ·David P. Humphreys, Neil Weir, Alastair D. G. Lawson, Andrew Mountain, Peter A. Lund	40
20	Human Protein Disulfide Isomerase Functionally Complements a dsbA Mutation and Enhances the Yield of Pectate Lyase C in Escherichia coli 1995 ·Journal of Biological Chemistry ·David P. Humphreys, Neil Weir, Andrew Mountain, Peter A. Lund	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact